Berlin, Germany: October 17–21, 2025 — Altis Labs, Inc. (“Altis”) is announcing results presented at the European Society for Medical Oncology (ESMO) Congress 2025: in the randomized, Phase III SWOG-0819 trial in advanced non–small cell lung cancer (aNSCLC), IPRO Response Rate (IRR) — an imaging-based endpoint derived from Altis’ IPRO survival prediction model — correlated more strongly with overall survival (OS) treatment effects than RECIST-defined Objective Response Rate (ORR).

In this analysis, IPRO scores were generated from baseline and follow-up CT scans from 1,034 patients in SWOG-0819. IPRO response was defined as a ≥30% improvement over baseline IPRO score. Patient-level and trial-level associations with OS were evaluated using landmarked survival analysis and a meta-analytic framework across predefined trial subgroups.

Key findings:

• Patients with an IPRO response at 8 weeks had significantly longer OS than non-responders
  (HR 0.64 [95% CI 0.54–0.75], p < 0.0001).
• RECIST ORR resulted in an unweighted R² of 0.05 when predicting OS across SWOG-0819 subgroups.
• IPRO Response Rate yielded an unweighted R² of 0.49, indicating a stronger correlation with OS treatment effects across subgroups.

IRR surrogacy outperformed RECIST ORR surrogacy for prediction of OS treatment effects across SWOG-0819 subgroups.

View the abstract here.

About Altis Labs

Altis Labs is the computational imaging company accelerating clinical trials with AI. Altis has trained proprietary AI models on the industry's largest multimodal training database spanning over 200 million longitudinal images linked to clinical, molecular, treatment, and outcomes data. Top 20 biopharmas use Altis’ AI models to more confidently analyze data from phase 1-4 clinical trials and bring the most effective novel treatments to patients sooner.For more information, visit www.altislabs.com, follow @AltisLabs on social media, or email info@altislabs.com.

Presented at ESMO Congress 2025, Berlin, Germany.
Poster #1911P

‍